Skip to main content
Premium Trial:

Request an Annual Quote

Natera Raises $55.5M

NEW YORK (GenomeWeb) – Natera today announced it has raised $55.5 million in a private round of financing to expand its sales and marketing operations, as well as its R&D. 

Sofinnova Ventures led the financing and were joined by Capital Research and Management, Franklin Templeton Investments, Jennison Associates, RA Capital Management, Healthcor Partners, and OrbiMed Advisors. 

The financing will go toward the development of existing products such as Natera's Panorama non-invasive prenatal test, the development of non-invasive cell-free DNA-based tests for the early detection and therapeutic monitoring of cancer, and clinical trials to demonstrate the utility of its tests in clinical practice, the San Carlos, Calif.-based firm said. 

In conjunction with the financing, James Healy, a general partner at Sofinnova, has joined Natera's board. 

The company previously raised $54.6 million in the spring of 2013. 

The Scan

Harvard Team Report One-Time Base Editing Treatment for Motor Neuron Disease in Mice

A base-editing approach restored SMN levels and improved motor function in a mouse model of spinal muscular atrophy, a new Science paper reports.

International Team Examines History of North American Horses

Genetic and other analyses presented in Science find that horses spread to the northern Rockies and Great Plains by the first half of the 17th century.

New Study Examines Genetic Dominance Within UK Biobank

Researchers analyze instances of genetic dominance within UK Biobank data, as they report in Science.

Cell Signaling Pathway Identified as Metastasis Suppressor

A new study in Nature homes in on the STING pathway as a suppressor of metastasis in a mouse model of lung cancer.